Pfizer and BioNTech announce positive topline data for mRNA-based combination vaccine program against influenza and COVID-19
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced positive topline results from a Phase 1/2 study (NCT05596734) evaluating the safety, tolerability and immunogenicity of mRNA-based combination vaccine candidates for influenza and COVID-19 among healthy adults 18 to 64 years of age.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news
More News: Covid Vaccine | COVID-19 | Influenza | Influenza Vaccine | Pfizer | Pharmaceuticals | Study | Vaccines